Few randomized controlled trials have been performed in AL amyloidosis and treatment has been substantially influenced by clinical practice in myeloma. It has become clear that the best prospects of survival and preservation or improvement in amyloid related organ function require as near complete ...
AA amyloidosis AA amyloidosis occurs in patients with chronic inflammation, which drives the accumulation of amyloid protein. It was previously more prevalent, however due to better treatment of chronic inflammatory conditions, it now accounts for <5% of cardiac cases. AA amyloidosis is associated with...
Cardio-Oncology and Heart Failure: AL Amyloidosis for the Heart Failure Clinician A Supplement to the Scientific Statement from the Heart Failure Society of America DOI: 10.1016/j.cardfail.2024.08.046 Heart Failure in Patients with Cancer – A Patient's Perspec...
1). Of note, these factors also form the foundation for clinical diagnosis and treatment strategies. Biomarkers can identify patients in the early stages, monitor disease progression, and evaluate the effectiveness of drugs.32,33,34,35 The hypotheses surrounding these pathogenic factors provide ...
Jonathan L. Kaufman, MD, discusses the significance of subcutaneous D-VCd in the treatment of patients with AL amyloidosis, remaining questions with the approach, and emerging strategies for those with high-risk cardiac features.
Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis Veena Mathew & Annabel K Wang Pages 1515-1525 | Published online: 06 May 2019 Cite this article CrossMark Full Article Figures & data References Citations Metrics Licensing Reprints & Permissions View PDF (...
Thus, given the importance of Ca2+ and Zn2+ homeostasis for brain functioning, strategies aimed at restoring the brain balance of these ions are emerging as promising avenues for the treatment of AD with several therapeutic approaches based on the so-called ‘metals hypothesis’ already showing en...
This review summarizes current cognitive enhancing approaches and addresses trends in the development of new symptomatic agents for the treatment of cognitive and behavioral abnormalities of AD. New directions in the treatment of cognitive enhancing agents are presented, and advances in the development of...
Data for 66 patients was recently Pomalidomide in multiple myeloma AA Chanan-Khan et al presented with the ORR being 56% and a median PFS of 5 months; this is comparable to other regimens used in advanced MM patients. The ORR and PFS were similar irrespective of previous treatment regimens....
For it transpired that their new-found euphoria wasn't just an understandable reaction to being cured of physical disease. MAOIs typically have mood-brightening properties as well. At the time, there was no accepted and clinically effective treatment for depression. Fortunately, via the usual ...